Findings

What do systematic reviews say?

4 questions · 4 findings · 2 reviews · Lung Cancer

No studies found 1 · 25%GRADE not reported 0 · 0%Very low 0 · 0%Low 1 · 25%Moderate 2 · 50%High 0 · 0%

Overall response rate · advanced anaplastic lymphoma kinase (ALK)‐rearranged non‐small cell lung cancer

ALK inhibitor probably leads to higher overall response rate compared with any cytotoxic chemotherapy (moderate certainty).

1 finding from 1 review

Overall response rate (ORR), · People with advanced non‐small cell lung cancer

Single‐immune checkpoint inhibitors (ICIs) may leads to higher overall response rate (ORR) compared with chemotherapy (low certainty).

1 finding from 1 review

Overall response rate (OSR) · People with advanced non‐small cell lung cancer

The review found no eligible studies for this question.

1 finding from 1 review

Overall response rate · advanced anaplastic lymphoma kinase (ALK)‐rearranged non‐small cell lung cancer

Next‐generation ALK inhibitor probably leads to higher overall response rate compared with crizotinib (moderate certainty).

1 finding from 1 review